NSTG NanoString Technologies Inc

More than 50 abstracts highlight the diverse capabilities of NanoString’s technologies in immuno-oncology, biomarker development and validation, and cancer characterization

NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today highlighted a record number of abstracts that will be presented at the American Society of Clinical Oncology (ASCO) conference being held June 1-5, 2018, in Chicago, Illinois.

“We’re proud of the extensive body of nCounter™-enabled research that is being presented at this year’s meeting of the American Society of Clinical Oncology,” said Brad Gray, NanoString’s president and CEO. “This includes important clinical applications of our products for current and potential diagnostic tests for immuno-oncology, breast cancer and lymphoma.”

At least 53 abstracts using NanoString’s technologies will be presented at ASCO, including applications of gene expression profiling in cancer and immuno-therapy using NanoString products like the PanCancer Panel family and IO 360™, as well as diagnostic applications such as subtyping breast cancer and lymphoma.

Below is a subset of abstracts that best illustrate the unique capabilities of NanoString’s technology platforms to span the continuum from biomarker targeted discovery to clinical applications.  A complete list of NanoString-enabled abstracts can be found in the table that follows.

Immuno-oncologyTitle: Adaptive phase II randomized trial of nivolumab after induction treatment in triple negative breast cancer (TONIC trial): Final response data stage I and first translational dataDate/Time: Monday, June 4, 2018, 3:00pm-4:30pm CTAuthor: Marleen Kok, MDPoster #/Location: 1012/Clinical Science Symposium, Hall D2Hyperlink: https://meetinglibrary.asco.org/record/160551/abstract

Title: Immune gene profiling of pretreatment tumor samples in "real-world" advanced melanoma patients treated with anti-PD-1 and/or anti-CTLA-4 Date/Time: Monday, June 4, 2018, 1:15pm-4:45pm CTAuthor: Elisa A. Rozeman, MDPoster #/Location: 9585/Board 412Hyperlink:  https://meetinglibrary.asco.org/record/163660/abstract

Title: Responses and durability in NSCLC treated with pegilodecakin and anti-PD-1Date/Time: Sunday, June 3, 2018, 8am-11:30am CTAuthor: Edward B. Garon, MDPoster #/Location: 9018/Board 341Hyperlink: https://meetinglibrary.asco.org/record/160279/abstract

Title: Pegilodecakin with nivolumab (nivo) or pembrolizumab (pembro) in patients (pts) with metastatic renal cell carcinoma (RCC)Date/Time: Monday, April 16 2018, 1pm-5:00pm CTAuthor: Nizar M. Tannir, MDPoster #/Location: 4509/Board 335Hyperlink: https://meetinglibrary.asco.org/record/161707/abstract

Title: Immune profiling of BRCA-mutated breast cancersDate/Time: Saturday, June 2, 2018, 8:00am-11:30am CTAuthor: Jeremy Meyer Force, DOPoster #/Location: 585/Board 77Hyperlink: https://meetinglibrary.asco.org/record/163391/abstract

Title: Interference between mutational load, immune signatures and outcome in patients with head and neck cancer treated with definitive chemoradiation: A multicenter study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)Date/Time: Saturday, June 2, 2018, 1:15pm-4:45pm CTAuthor: Inge Tinhofer, PhDPoster #/Location: 6047/Board 35Hyperlink: https://meetinglibrary.asco.org/record/162474/abstract

Title: Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with melanoma progressing on or after a PD-1/L1 blocking antibodyDate/Time: Monday, June 4, 2018, 1:15pm-4:45pm CTAuthor: Sanjiv S. Agarwala, MDPoster #/Location: 9530/Board 357Hyperlink: https://meetinglibrary.asco.org/record/163453/abstract

Title: Efficacy and genetic analysis for a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic immunotherapy, and ipilimumab combination treatment in patients with stage IIIb-IV unresectable or metastatic melanomaDate/Time: Monday, June 4, 2018, 1:15pm-4:45pm CTAuthor: Robert Hans Ingemar Andtbacka, MDPoster #/Location: 9541/Board 368Hyperlink: https://meetinglibrary.asco.org/record/163701/abstract

Title: Immune profiling of pre- and post-treatment breast cancer tissues from the S0800 randomized neoadjuvant trial of weekly nab-paclitaxel with or without bevacizumab and dose dense doxorubicin and cyclophosphamideDate/Time: Saturday, June 2, 2018, 8:00am-11:30am CTAuthor: Xiaotong Li, PhDPoster #/Location: 578/Board 70Hyperlink: https://meetinglibrary.asco.org/record/162778/abstract

Title: Association between adaptive immune signature and outcome in HER2-positive breast cancer treated with trastuzumab and lapatinib in the NCCTG-N9831 (Alliance) and NeoALTTO trialsDate/Time: Monday, April 16 2018, 1pm-5:00pm CTAuthor: Saranya Chumsri, MDPoster #/Location: 577/Board 69Hyperlink: https://meetinglibrary.asco.org/record/162783/abstract

Lymphoma Sub-typing (Lymphmark™)Title: Results of real-time cell-of-origin subtype identification by gene expression profiling in patients with ABC-type diffuse large B-cell lymphoma in the phase III trial of lenalidomide plus R-CHOP vs placebo plus R-CHOP (ROBUST)Date/Time: Monday, June 4, 2018, 8am-11:30am CTAuthor: Grzegorz S. Nowakowski, MDPoster #/Location: 7548/Board 185Hyperlink: https://meetinglibrary.asco.org/record/162322/abstract

Title: Acalabrutinib monotherapy in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).Date/Time: Monday, June 4, 2018, 1pm-5:00pm CTAuthor: Martin JS Dyer, PhDPoster #/Location: 7547/Board 184Hyperlink: https://meetinglibrary.asco.org/record/162360/abstract

Title: Dose-adjusted (DA)-EPOCH-R with high-dose methotrexate (HD-MTX) for newly diagnosed stage II-IV CD5-positive diffuse large B-cell Iymphoma (CD5+ DLBCL): Primary analysis of PEARL5 studyDate/Time: Monday, June 4, 2018, 8am-11:30am CTAuthor: Kana Miyazaki, MD, PhDPoster #/Location: 7561/Board 198Hyperlink: https://meetinglibrary.asco.org/record/162387/abstract

Breast Cancer (Prosigna®-PAM50)Title: SOLTI-1303 PATRICIA: A phase II study of palbociclib and trastuzumab (HR+ with or without letrozole) in trastuzumab‐pretreated, postmenopausal patients with HER2‐positive metastatic breast cancerDate/Time: Saturday, June 2, 2018, 8am-11:30am CTAuthor: Patricia Villagrasa, PhDPoster #/Location: TPS1101/Board 181bHyperlink: https://meetinglibrary.asco.org/record/165311/abstract

Title: PAM50 HER2-enriched/ERBB2-high (HER2-E/ERBB2H) biomarker to predict response and survival following lapatinib (L) alone or in combination with trastuzumab (T) in HER2+ T-refractory metastatic breast cancer (BC): A correlative analysis of the EGF104900 phase III trial.Date/Time: Saturday, June 2, 2018, 1pm-5:00pm CTAuthor: Tomás Pascual, MDPoster #/Location: 1025/Board 106Hyperlink: https://meetinglibrary.asco.org/record/161762/abstract

Title: HER2-enriched subtype and ERBB2 mRNA as predictors of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer: A combined analysis of TBCRC006/023 and PAMELA trials.Date/Time: Saturday, June 2, 2018, 8am-11:30am CTAuthor: Aleix Prat, MD, PhDPoster #/Location: 509/Board 1Hyperlink: https://meetinglibrary.asco.org/record/161696/abstract

Title: Intrinsic subtypes of HER2-positive breast cancer and their associations with pathologic complete response (pCR) and outcomes: Findings from NSABP B-41, a randomized neoadjuvant trialDate/Time: Saturday, June 2, 2018, 8am-11:30am CTAuthor: Sandra M. Swain, MDPoster #/Location: 580/Board 72Hyperlink: https://meetinglibrary.asco.org/record/162624/abstract

Abstract #		Title		Hyperlink
578		Immune profiling of pre- and post-treatment breast cancer tissues from the S0800 randomized neoadjuvant trial of weekly nab-paclitaxel with or without bevacizumab and dose dense doxorubicin and cyclophosphamide		https://meetinglibrary.asco.org/record/162778/abstract
1533		Genomic profiling of tumors from patients with germline BRCA mutations		https://meetinglibrary.asco.org/record/163711/abstract
577		Association between adaptive immune signature and outcome in HER2-positive breast cancer treated with trastuzumab and lapatinib in the NCCTG-N9831 (Alliance) and NeoALTTO trials		https://meetinglibrary.asco.org/record/162783/abstract
585		Immune profiling of BRCA-mutated breast cancers		https://meetinglibrary.asco.org/record/163391/abstract
4509		Pegilodecakin with nivolumab (nivo) or pembrolizumab (pembro) in patients (pts) with metastatic renal cell carcinoma (RCC)		https://meetinglibrary.asco.org/record/161707/abstract
TPS1101		SOLTI-1303 PATRICIA: A phase II study of palbociclib and trastuzumab ﴾HR+ with or without letrozole﴿ in trastuzumab‐pretreated, postmenopausal patients with HER2‐positive metastatic breast cancer		https://meetinglibrary.asco.org/record/165311/abstract
6059		Gene expression signature after one dose of neoadjuvant pembrolizumab associated with tumor response in head and neck squamous cell carcinoma (HNSCC)		https://meetinglibrary.asco.org/record/163405/abstract
2027		Angiotensinogen gene silencing to predict bevacizumab response in recurrent glioblastoma patients		https://meetinglibrary.asco.org/record/164151/abstract
6047		Interference between mutational load, immune signatures and outcome in patients with head and neck cancer treated with definitive chemoradiation: A multicenter study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)		https://meetinglibrary.asco.org/record/162474/abstract
1022		First-line ribociclib (RIB) + letrozole (LET) in hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-2 biomarker analyses		https://meetinglibrary.asco.org/record/158537/abstract
11536		Interrogating the sarcoma immune microenvironment (iME) using multiplex immunohistochemistry (mIHC)		https://meetinglibrary.asco.org/record/162153/abstract
6017		Phase II multi-site investigation of neoadjuvant pembrolizumab and adjuvant concurrent radiation and pembrolizumab with or without cisplatin in resected head and neck squamous cell carcinoma		https://meetinglibrary.asco.org/record/161539/abstract
1025		PAM50 HER2-enriched/ERBB2-high (HER2-E/ERBB2H) biomarker to predict response and survival following lapatinib (L) alone or in combination with trastuzumab (T) in HER2+ T-refractory metastatic breast cancer (BC): A correlative analysis of the EGF104900 phase III trial		http://www.abstractsonline.com/pp8/#!/4562/presentation/2737
509		HER2-enriched subtype and ERBB2 mRNA as predictors of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer: A combined analysis of TBCRC006/023 and PAMELA trials		https://meetinglibrary.asco.org/record/161696/abstract
580		Intrinsic subtypes of HER2-positive breast cancer and their associations with pathologic complete response (pCR) and outcomes: Findings from NSABP B-41, a randomized neoadjuvant trial		https://meetinglibrary.asco.org/record/162624/abstract
9018		Responses and durability in NSCLC treated with pegilodecakin and anti-PD-1		https://meetinglibrary.asco.org/record/160279/abstract
9585		Immune gene profiling of pretreatment tumor samples in "real-world" advanced melanoma patients treated with anti-PD-1 and/or anti-CTLA-4		https://meetinglibrary.asco.org/record/163660/abstract
5569		Gene expression profiling using Nanostring technology to predict surgical outcome in advanced primary high grade serous ovarian cancer (HGSOC) patients (pts). Study of the Tumor Bank Ovarian Cancer (TOC)		https://meetinglibrary.asco.org/record/161743/abstract
1012		Adaptive phase II randomized trial of nivolumab after induction treatment in triple negative breast cancer (TONIC trial): Final response data stage I and first translational data		https://meetinglibrary.asco.org/record/160551/abstract
9559		Analysis of the kinetics and effects of vemurafenib (V) + cobimetinib (C) on intratumoral and host immunity in patients (pts) with BRAFV600 mutant melanoma (BRAFmM): Implications for combination with immunotherapy		https://meetinglibrary.asco.org/record/163593/abstract
9530		Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with melanoma progressing on or after a PD-1/L1 blocking antibody		https://meetinglibrary.asco.org/record/163453/abstract
7547		Acalabrutinib monotherapy in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)		https://meetinglibrary.asco.org/record/162360/abstract
12057		Association of Akt inhibition with change in immunophenotype of tumor microenvironment (TME) in breast cancer (BC)		https://meetinglibrary.asco.org/record/164519/abstract
9580		Quantitative multiplex immunofluorescence (qmIF) and genomic evaluation of tumor microenvironment (TME) to identify candidate biomarkers in stage II/III melanoma		https://meetinglibrary.asco.org/record/163527/abstract
9576		Validation of a prognostic 53-immune-gene panel in stage II/III melanoma		https://meetinglibrary.asco.org/record/163447/abstract
5583		A gene expression prognostic signature for overall survival in patients with high-grade serous ovarian cancer		https://meetinglibrary.asco.org/record/161604/abstract
5585		Histone deacetylase inhibition alters tumor phenotype and stimulates a productive anti-tumor immune response in preclinical models of ovarian cancer		https://meetinglibrary.asco.org/record/161683/abstract
TPS2617		A phase 2A open-label, multicenter trial of the safety and efficacy of LYC-55716, a first-in-class oral, small-molecule RORγ agonist to treat select solid tumors		https://meetinglibrary.asco.org/record/165349/abstract
9574		Mutational and immune gene expression profiling at relapse in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (pbo) in the COMBI-AD trial		https://meetinglibrary.asco.org/record/163696/abstract
7561		Dose-adjusted (DA)-EPOCH-R with high-dose methotrexate (HD-MTX) for newly diagnosed stage II-IV CD5-positive diffuse large B-cell Iymphoma (CD5+ DLBCL): Primary analysis of PEARL5 study		https://meetinglibrary.asco.org/record/162387/abstract
12072		A cell cycle-related RNA expression signature of neoantigen burden in lung adenocarcinoma		https://meetinglibrary.asco.org/record/164866/abstract
5566		Inhibition of the Wnt/β-catenin pathway to promote T-cell immunity and survival in a syngeneic mouse model of ovarian cancer		https://meetinglibrary.asco.org/record/163525/abstract
3089		Pelareorep to promote the expression of a IFN-gamma-related gene signature that predicts response to checkpoint blockade therapy		https://meetinglibrary.asco.org/record/159180/abstract
7548		Results of real-time cell-of-origin subtype identification by gene expression profiling in patients with ABC-type diffuse large B-cell lymphoma in the phase III trial of lenalidomide plus R-CHOP vs placebo plus R-CHOP (ROBUST)		https://meetinglibrary.asco.org/record/162322/abstract
9541		Efficacy and genetic analysis for a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic immunotherapy, and ipilimumab combination treatment in patients with stage IIIb-IV unresectable or metastatic melanoma		https://meetinglibrary.asco.org/record/163701/abstract
3076		Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancers		https://meetinglibrary.asco.org/record/159233/abstract
507		De-escalated treatment with trastuzumab-pertuzumab-letrozole in patients with HR+/HER2+ operable breast cancer with Ki67 response after 2 weeks letrozole: Final results of the PerELISA neoadjuvant study		https://meetinglibrary.asco.org/record/160260/abstract
e15139		Characterization of the colorectal cancer immune microenvironment using a novel high-plex protein analysis technology		https://meetinglibrary.asco.org/record/159318/abstract
e24243		Gene expression signature development to decode breast cancer heterogeneity		https://meetinglibrary.asco.org/record/164473/abstract
e17063		Dynamic variations in gene expressions of circulating tumor cells in metastatic castration-resistant prostate cancer patients in response to androgen receptor signaling inhibitors		https://meetinglibrary.asco.org/record/161398/abstract
e18015		Comprehensive analysis of mutation and expression based pathways in head and neck squamous cell carcinoma		https://meetinglibrary.asco.org/record/165024/abstract
e21610		Effect of combination immunotherapy on tumor growth, survival, and intratumoral immune infiltration in transgenic murine model of melanoma		https://meetinglibrary.asco.org/record/163694/abstract
e16579		Immune-related expression profiles and sunitinib response in metastatic clear cell renal cell carcinoma (ccRCC)		https://meetinglibrary.asco.org/record/160470/abstract
e17072		Detection of clinically-actionable alterations as hallmarks of de novo small cell prostate cancer		https://meetinglibrary.asco.org/record/161350/abstract
e16554		Association of gene expression with outcomes with everolimus as post-VEGF inhibitor therapy for renal cell carcinoma (RCC)		https://meetinglibrary.asco.org/record/160603/abstract
e21600		Quantitative multiplex immunofluorescence to identify candidate biomarkers of response to anti-PD1 in metastatic melanoma		https://meetinglibrary.asco.org/record/163510/abstract
e16024		Transcriptional analysis of immune genes in Epstein-Barr virus-associated gastric cancer and association with clinical outcomes		https://meetinglibrary.asco.org/record/164795/abstract
e15593		The immune-profile of mismatch repair deficient (dMMR) colorectal cancers (CRCs) differs according to primary tumor sidedness		https://meetinglibrary.asco.org/record/158896/abstract
e21578		T-cell biological aging in melanoma: Impact on immunotherapeutic discontinuation		https://meetinglibrary.asco.org/record/163497/abstract
e15121		Development of predictors for PD-1/PD-L1-directed therapy of non-small cell lung cancer (NSCLC) by gene expression profiling of small diagnostic biopsies (DBX)		https://meetinglibrary.asco.org/record/159447/abstract
e18017		Investigating the feasibility of targeted next-generation sequencing to guide the treatment of head and neck squamous cell carcinoma		https://meetinglibrary.asco.org/record/165021/abstract
e12634		Different pCR rates according PAM50 defined subtypes in HER2 positive early breast cancer treated with neoadjuvant pertuzumab and trastuzumab		https://meetinglibrary.asco.org/record/162921/abstract

About NanoString Technologies, Inc.NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter® Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 1,950 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company collaborates with biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.

For more information, please visit www.nanostring.com.

NanoString, NanoString Technologies, the NanoString logo, IO360, nCounter and Prosigna are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions. All third party trademarks are the property of their respective owners.

Contact:

Doug FarrellVice President, Investor Relations & Corporate Communicationsdfarrell@nanostring.comPhone: 206-602-1768